| Oral anticoagulant (OA) | VKA | NOA | VKA + NOA |
|---|---|---|---|
| Population and haemorrhagic risk factors | |||
| Average age | 83.1 | 78.9 | 81 |
| Sex ratio (female/male) | 1.08 | 1.5 | 1.29 |
| BMI < 18.5 | 10% | 2% | 6% |
| Kidney failure | 42% | 26% | 34% |
| Hypertension | 66% | 72% | 69% |
| Heart failure > 2NYHA | 18% | 12% | 15% |
| CHADS2-VASc score | 4.38 | 4.12 | 4.25 |
| HAS BLED | 2.52 | 2.26 | 2.39 |
| Prescription | |||
| OA | 62% fluindione 38% warfarin | 74% rivaroxaban 26% dabigatran | 50% VKA 50% NOA |
| Introduction to hospital | 7% | 22% | 14.5% |
| Class Switch OA | 28% | 12% | 20% |
| Continued OA | 65% | 66% | 65.5% |
| Number of non-recommended drug interactions | 2.32 | 0.42 | 1.37 |
| Side effects | |||
| Gastrointestinal bleeding | 10% | 6% | 8% |
| Renal haemorrhage | 2% | 0% | 1% |
| Stroke | 10% | 10% | 10% |
| Other | 8% | 4% | 6% |